SYRE
NASDAQ HealthcareSpyre Therapeutics, Inc. - Common Stock
Biotechnology
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ร7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 ย anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ร7 and anti-TL1A mAbs; SPY130, a combination anti-a4ร7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
๐ Market Data
| Price | $69.42 |
|---|---|
| Volume | 1,429,103 |
| Market Cap | 5.99B |
| Beta | 2.940 |
| RSI (14-Day) | 58.9 |
| 200-Day MA | $31.23 |
| 50-Day MA | $52.18 |
| 52-Week High | $76.00 |
| 52-Week Low | $12.29 |
| Forward P/E | -22.98 |
| Price / Book | 9.70 |
๐ฏ Investment Strategy Scores
SYRE scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (98/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SYRE in your text
Paste any article, transcript, or post โ the tool will extract SYRE and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.